Particulate implants and biodegradable fiducial markers
Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation.
1. A process for making an implantable system comprising preparing a hydrogel matrix comprising covalently attached radioopaque agents and breaking the matrix into a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles wherein the matrix has a porosity of at least about 30% by volume and the radioopaque agent is present at a concentration of at least about 0.1% w/w, with the particles being biodegradable to produce only water soluble degradation products.
2. The process of claim 1 wherein the hydrogel matrix is formed by reacting a first precursor and wherein the first precursor further comprises the radioopaque agent.
3. The method of claim 2 wherein the radioopaque agent comprises iodine.
4. A process for making an implantable system comprising preparing a hydrogel matrix comprising covalently attached radioopaque agents and breaking the matrix into a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles wherein the hydrogel matrix is formed by reacting a first precursor and wherein the first precursor further comprises the radioopaque agent and wherein the first precursor comprises a branched polyethylene glycol, with the radioopaque agent being disposed on at least one of the branches.
5. The process of claim 1 wherein the matrix is passed through a mesh at least twice to form the particles.
6. A process for making an implantable system comprising preparing a hydrogel matrix comprising covalently attached radioopaque agents and breaking the matrix into a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles wherein the matrix is passed through a first mesh having about 50 microns between mesh strands and is then passed through a second mesh having about 20 microns between mesh strands.
7. The process of claim 1 wherein the matrix is formed from a first precursor comprising a plurality of first functional groups and a second precursor comprising a plurality of second functional groups, with the first functional groups forming covalent bonds with the second functional groups to thereby form the matrix.
8. The process of claim 1 wherein breaking the matrix for preparing the particles comprises grinding, milling, or chopping.
9. The process of claim 7 wherein the plurality of first functional groups comprises an electrophilic functional group and wherein the plurality of second functional groups comprises a nucleophilic functional group.
10. The process of claim 1 wherein the matrix is formed from a first precursor species wherein the first precursor species comprises 3 to 16 nucleophilic functional groups and a second precursor species wherein the second precursor species comprises 2 to 12 electrophilic functional groups.
11. The process of claim 1 wherein the matrix has a CT number of at least about 80.
12. The process of claim 1 comprising iodine in a concentration in the matrix of 0.1% to 3%.
13. The process of claim 1 wherein the covalently attached radioopaque agents comprise iodine.
14. The process of claim 1 wherein the covalently attached radiopaque agents comprise a phenyl ring compound.
15. The process of claim 14 wherein the phenyl ring compound is at least one compound selected from the group consisting of 2,3,5-triiodobenzoic acid, 3,4,5-triiodophenol, erythrosine, rose bengal, 3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid, and 3,5-Diacetamido-2,4,6-triiodobenzoic acid.
16. The process of claim 1 further comprising separating the covalently-crosslinked hydrogel particles into collections with desired size ranges and distributions of sizes wherein one of the collections consists of particles between about 10 microns and about 500 microns.
17. The process of claim 1 wherein the hydrogel matrix has a solids content between about 2.5% and about 20%.
18. The process of claim 1 wherein the covalently-crosslinked hydrogel particles have a weight that increases no more than about 50% upon exposure to a physiological solution in the absence of physical restraints for twenty-four hours relative to a weight of the hydrogel at the time of formation.
19. The process of claim 1 wherein the particles comprise a therapeutic agent.